Enanta Pharmaceuticals Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ENTA Nasdaq 2834 https://www.enanta.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference - Sep 17th, 2023 4:00 pm
Enanta Pharmaceuticals to Present Data for EDP-938, its Oral, Once-Daily, N-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2023 - Sep 7th, 2023 11:00 am
Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600 - Sep 1st, 2023 10:51 pm
Enanta Pharmaceuticals to Participate in Investor Conferences in September - Aug 31st, 2023 11:00 am
Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade - Aug 13th, 2023 12:08 pm
Why Shares of Enanta Pharmaceuticals Are Dropping Tuesday - Aug 8th, 2023 6:23 pm
Q3 2023 Enanta Pharmaceuticals Inc Earnings Call - Aug 8th, 2023 2:42 pm
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates - Aug 7th, 2023 9:15 pm
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter with Conference Call and Webcast Today at 4:30 p.m. ET - Aug 7th, 2023 8:01 pm
Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Third Quarter Ended June 30, 2023 - Jul 31st, 2023 11:00 am
Are Options Traders Betting on a Big Move in Enanta Pharmaceuticals (ENTA) Stock? - Jun 21st, 2023 12:36 pm
Enanta Pharmaceuticals Announces Positive Data From a Phase 1 Clinical Study of EDP-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus - Jun 20th, 2023 11:00 am
Enanta Pharmaceuticals Announces Data Presentation at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2023 - Jun 7th, 2023 11:00 am
Enanta Pharmaceuticals to Participate at Jefferies Global Healthcare Conference - May 31st, 2023 11:00 am
Enanta Pharmaceuticals to Participate in Two Investor Conferences in May - May 9th, 2023 11:00 am
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates - May 8th, 2023 9:15 pm
Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19 - May 8th, 2023 8:01 pm
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Conference Call and Webcast Today at 4:30 p.m. ET - May 8th, 2023 8:01 pm
Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2023 - May 2nd, 2023 8:01 pm
Enanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET® (U.S.)/MAVIRET® (ex-U.S.) (Glecaprevir/Pibrentasvir) to OMERS Life Sciences for $200 Million - Apr 25th, 2023 12:01 pm